Vosaroxin (formerly SNS-595) in Phase 1 and 2 Clinical Trials
The PHASE 2 REVEAL-1 (Response Evaluation of Voreloxin in Elderly AML) study of Vosaroxin will evaluate the safety and anticancer activity of Vosaroxin as a treatment for patients over 60 years of age with previously untreated acute myeloid leukemia. This open label, multicenter trial is currently enrolling patients.
Acute myeloid leukemia is a blood cancer that is mostly seen in older patients (most patients are over the age of 60). The standard treatment for patients would include a class of drugs known as anthracyclines (such as daunorubicin) and a class of drugs known as nucleoside analogues (such as cytarabine). Older patients with leukemia typically do not respond as well to this therapy compared to younger patients for a number of reasons such as their overall health and the nature of the disease.
The unique identifier for this study on ClinicalTrials.gov is SPO-0014.
This is a Phase 1b study of Vosaroxin in combination with cytarabine as a treatment for patients with acute leukemia. The study currently is enrolling patients.
Leukemia is a cancer that starts in blood-forming tissues such as the bone marrow and causes a large number of blood cells to be produced and enter the blood stream. It is estimated that there will be over 44,000 new cases diagnosed in the United States in 2007.
The unique identifier for this study on ClinicalTrials.gov is SPO-0014.
This study is for Ovarian cancer is a disease that forms in the tissues of the ovary (one of a pair of female reproductive glands in which the ova, or eggs, are formed). Most ovarian cancers are either ovarian epithelial carcinomas (cancer that begins in the cells on the surface of the ovary) or malignant germ cell tumors (cancer that begins in egg cells). The American Cancer Society estimates that more than 21,000 women will be diagnosed with ovarian cancer in the United States this year. After an initial response to therapy, recurrence rates are unfortunately very high, in spite of advances in cancer treatment. Vosaroxin as a treatment for women 18 years or older with ovarian cancer who previously have received treatment with a platinum-based chemotherapeutic drug regimen and now have relapsed.
Ovarian cancer is a disease that forms in the tissues of the ovary (one of a pair of female reproductive glands in which the ova, or eggs, are formed). Most ovarian cancers are either ovarian epithelial carcinomas (cancer that begins in the cells on the surface of the ovary) or malignant germ cell tumors (cancer that begins in egg cells). The American Cancer Society estimates that more than 21,000 women will be diagnosed with ovarian cancer in the United States this year. After an initial response to therapy, recurrence rates are unfortunately very high, in spite of advances in cancer treatment.
The unique identifier for this study on ClinicalTrials.gov is SPO-0010.
